5 Key Takeaways

• 1

  In the phase 2b/3 BRUNELLO trial, both remigromig doses met the primary endpoint of noninferiority to monthly ranibizumab for visual acuity gains in DME at week 52.

• 2

  Mean BCVA gains at week 52 were 9.1 ETDRS letters with remigromig 0.5 mg, 8.7 letters with 0.8 mg, and 11.8 letters with ranibizumab.

• 3

  Neither remigromig dose was superior to ranibizumab for visual acuity or central subfield thickness, the trial’s key secondary endpoints.

• 4

  PDR-related adverse events occurred in 6.7% and 6.1% of patients receiving remigromig 0.5 mg and 0.8 mg, respectively, versus 0.9% with ranibizumab.

• 5

  The randomized, double-masked trial enrolled 984 adults with DME, and its second year will evaluate personalized treatment intervals.